Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors

Patients with lung adenocarcinoma harboring common epidermal growth factor receptor (<i>EGFR</i>) mutations usually have a good response rate (RR) and longer progression-free survival (PFS) to <i>EGFR</i> tyrosine kinase inhibitors (TKIs). However, the treatment efficacy to u...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Ming-Ju Tsai, Jen-Yu Hung, Mei-Hsuan Lee, Chia-Yu Kuo, Yu-Chen Tsai, Ying-Ming Tsai, Ta-Chih Liu, Chih-Jen Yang, Ming-Shyan Huang, Inn-Wen Chong
Formato: Artigo
Idioma:Inglês
Publicado: MDPI AG 2018-11-01
Series:Cancers
Assuntos:
lung cancer
adenocarcinoma
gefitinib
erlotinib
afatinib
elderly
epidermal growth factor receptor
tyrosine kinase inhibitor
Acceso en liña:https://www.mdpi.com/2072-6694/10/11/434
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares